Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM.
Rohan KheraLovedeep Singh DhingraArya AminorroayaKelly LiJin J ZhouFaaizah ArshadClair BlacketerMary G BowringFan BuMichael CookDavid A DorrTalita Duarte SallesScott L DuVallThomas FalconerTina E FrenchElizabeth E HanchrowScott HorbanWallis C Y LauJing LiYuntian LiuYuan LuKenneth Kc ManMichael E MathenyNestoras MathioudakisMichael F McLemoreEvan MintyDaniel R MoralesPaul NagyAkihiko NishimuraAnna OstropoletsAndrea PistilloJose D PosadaNicole PrattCarlen ReyesJoseph R RossSarah SeagerNigam ShahKatherine SimonEric Yf WanJianxiao YangCan YinSeng Chan YouMartijn J SchuemiePatrick B RyanGeorge HripcsakHarlan KrumholzMarc A SuchardPublished in: BMJ medicine (2023)
Despite the increase in overall uptake of cardioprotective antihyperglycaemic drugs as second line treatments for type 2 diabetes mellitus, their uptake was lower in patients with cardiovascular disease than in people with no cardiovascular disease over the past decade. A strategy is needed to ensure that medication use is concordant with guideline recommendations to improve outcomes of patients with type 2 diabetes mellitus.